Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Abstract

COVID-19 has rapidly developed into a worldwide pandemic with a significant health and economic burden. There are currently no approved treatments or preventative therapeutic strategies. Hundreds of clinical studies have been registered with the intention of discovering effective treatments. Here, we review currently registered interventional clinical trials for the treatment and prevention of COVID-19 to provide an overall summary and insight into the global response.

Keywords: 2019-nCoV; COVID-19; SARS-CoV-2; coronavirus; pandemic.

Figure 1

Flow Diagram Showing the Study Selection Process of Clinical Trials Discussed in This Article and Listed in Table 1 in the Main Text. Data in the WHO International Clinical Trials Registry were incorporated from various national registries, including those from Australia, New Zealand, China, The Netherlands, Brazil, India, Cuba, Republic of Korea, Germany, Iran, Japan, Sri Lanka, Thailand, and Peru, and also ClinicalTrials.gov, EU Clinical Trials registry, International Standard Randomised Controlled Trial Number (ISRCTN)xi, and the Pan-African registries. Three studies included treatment for patients with COVID-19 and an intervention to prevention infection in uninfected patients.

Figure 2

First Recording (Week Commencing) of Clinical Trials for COVID-19 in Registry by Country (Primary Sponsor/Principal Investigator Origin). Data are from registries in Australia, New Zealand, China, The Netherlands, Brazil, India, Cuba, Republic of Korea, Germany, Iran, Japan, Sri Lanka, Thailand, and Peru, and also ClinicalTrials.gov, EU Clinical Trials registry, International Standard Randomised Controlled Trial Number (ISRCTN), and the Pan-Africa registries.